December 20, 2021
1 min watch
Save
VIDEO: ‘Interesting’ real-world data on sickle cell treatment from ASH
In this video, Matthew M. Heeney, MD, highlighted “interesting” real-world and long-term follow-up studies for the treatment of sickle cell that were presented at ASH Annual Meeting and Exposition.
“They’re gradually moving out to the phase 2/3, sort of more pivotal, trial range,” Heeney, associate chief of hematology and director of the Sickle Cell Program at Dana-Farber/Boston Children’s Cancer and Blood Disorder Center and associate professor at Harvard Medical School, said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Heeney reports consulting for AstraZeneca, Cyclerion Therapeutics, Inc., Forma Therapeutics, Inc., Global Blood Therapeutics, Inc., Micelle BioPharma, Novartis Pharmaceuticals Corporation, Pfizer, and Vertex Pharmaceuticals, Inc./CRISPR Therapeutics; and receiving grant or research support from AstraZeneca, Global Blood Therapeutics and Novartis Pharmaceuticals Corporation.